Bayer’s Pipeline Advances in China and US, but Debt and Cash Burn Overshadow the Rally
24.05.2026 - 12:34:01 | boerse-global.de
The German life sciences group is displaying a classic case of good news and bad news colliding. While two regulatory green lights for its heart and kidney drug Kerendia (finerenone) bolster the pharma pipeline, a €32.5 billion net financial debt pile and a €2.3 billion quarterly cash outflow are keeping the stock pinned below a key technical level.
On 22 May 2026, China’s NMPA approved Kerendia for adults with symptomatic chronic heart failure and a left ventricular ejection fraction of at least 40%. That expands the drug’s footprint beyond its original indication in chronic kidney disease with type 2 diabetes. The decision rests on the Phase III FINEARTS-HF study, which enrolled roughly 6,000 patients across 37 countries and showed a significant reduction in cardiovascular deaths and heart failure events versus placebo. A day earlier, the FDA accepted a supplemental new drug application for finerenone in chronic kidney disease paired with type 1 diabetes, granting an accelerated review based on the Phase III FINE-ONE trial, where the drug lowered the urine albumin-to-creatinine ratio by 25% over six months compared to placebo.
That regulatory momentum is already visible in the first?quarter 2026 numbers. Kerendia posted currency? and portfolio?adjusted growth of 84.2%, while the prostate cancer drug Nubeqa climbed 57.1%. Yet patent expirations for Xarelto and generic competition for Eylea continue to weigh on the topline. Group revenue rose a currency?adjusted 4.1% to €13.4 billion, and earnings before interest, tax, depreciation and amortisation (EBITDA) before special items came in at €4.5 billion. The adjusted operating result, a different metric, increased 9% to €4.45 billion, according to the company’s financial statements.
Should investors sell immediately? Or is it worth buying Bayer?
The real drag, however, sits on the balance sheet. Net financial debt swelled to roughly €32.5 billion by the end of March, driven by hefty settlement payments in the US. Free cash flow turned negative to the tune of €2.3 billion in the first quarter alone. The agricultural division Crop Science provided some offset with a currency?adjusted revenue gain of 4%, but the overall picture has forced Bayer to accelerate its “Dynamic Shared Ownership” efficiency programme. Management is expected to lay out concrete debt?reduction steps at the Deutsche Bank European Champions Conference in Frankfurt on Wednesday.
The stock’s reaction has been muted at best. Shares closed Friday at €38.39, down nearly 2% on the day and sitting just below the 50?day moving average of €38.91. The 52?week high of €49.17 is still about 22% away. The relative strength index (RSI) of 70.3 signals a short?term overbought condition that could add headwinds. Over a 12?month horizon, however, the stock has eked out a 1% gain, lifted by a roughly 58% recovery from the May 2025 trough.
Analysts at DZ Bank and UBS remain constructive, maintaining buy ratings on the argument that litigation risks are largely priced in and the market is underestimating the pharma pipeline. Beyond finerenone, Bayer’s Factor XIa inhibitor recently secured Priority Review status from the FDA, adding another potential catalyst. Investors will also be watching the US Supreme Court, which is expected to rule on key legal precedents by the end of June – a decision that could significantly affect Bayer’s future settlement burden.
For now, the clock is ticking on whether regulatory tailwinds from finerenone can outrun the fundamental headwinds of debt, litigation costs, and patent cliffs. The next quarterly results, combined with the FDA’s verdict on type?1 diabetes and the Supreme Court’s stance, will provide the clearest test yet of Bayer’s ability to balance its pipeline promise with its financial realities.
Ad
Bayer Stock: New Analysis - 24 May
Fresh Bayer information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
